Diagnostic Approach to Systemic Autoimmune Rheumatic Diseases and Wilson's Disease

Introduction to Diagnostic Testing

The American College of Rheumatology recommends testing for ANA when evaluating unexplained joint pain, skin rashes, or neurological symptoms, as these are cardinal features of systemic autoimmune rheumatic diseases, with a screening dilution of 1:160 representing the 95th percentile of healthy controls 1, 2, 3, 4
The European Association for the Study of the Liver (EASL) guidelines state that Wilson's disease should be considered in any individual with liver abnormalities or neurological movement disorders of uncertain cause, and age alone should not eliminate the diagnosis, with serum ceruloplasmin levels <200 mg/L having a low positive predictive value 1, 2, 6

The American College of Rheumatology recommends indirect immunofluorescence assay (IIFA) on HEp-2 cells as the reference method for ANA screening, with a threshold providing 95.8% sensitivity and 86.2% specificity for systemic autoimmune rheumatic diseases 3, 4
Up to 25% of healthy individuals can test ANA-positive depending on demographics and test variables, so clinical context is essential, with a positive ANA at low titer (1:40-1:80) occurring in up to 31.7% of healthy individuals 3, 4
ANA testing should not be used for disease monitoring—it is a diagnostic test only, and a negative ANA does not exclude autoimmune disease; sensitivity is not 100% even at 1:160 3, 4

The EASL guidelines recommend testing for ceruloplasmin when neurological abnormalities are present, particularly in children and adults through middle age with unexplained hepatic or neurologic symptoms, with a serum ceruloplasmin level <50 mg/L being strong evidence for Wilson's disease 1, 2, 6
Normal ceruloplasmin does not exclude Wilson's disease—approximately 10-20% of Wilson's disease patients have normal levels, and ceruloplasmin is an acute phase reactant and may be falsely elevated during inflammation or infection 1, 2, 6

For joint pain and skin rashes, order ANA by IIFA on HEp-2 cells at 1:160 dilution, and if ANA positive, request both titer and pattern reporting, with reflex testing based on pattern 3, 4, 7
For neurological abnormalities, first determine if hepatic involvement is present, and if hepatic or psychiatric features coexist with neurological symptoms, order ceruloplasmin immediately, with a slit-lamp examination for Kayser-Fleischer rings 1, 2, 6
For combined symptoms (joint pain + neurological + rash), order both ANA and ceruloplasmin simultaneously, with comprehensive metabolic panel, complete blood count, urinalysis, and consideration of antiphospholipid antibodies if thrombotic history present 1, 5, 7

When ordering ANA or ceruloplasmin, include complete blood count with differential, comprehensive metabolic panel, urinalysis with protein/creatinine ratio, and inflammatory markers (ESR, CRP) 4, 7
For ceruloplasmin testing specifically, add 24-hour urinary copper excretion, serum copper, liver function tests, and slit-lamp ophthalmologic examination 1, 2, 6